{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:48:23Z","timestamp":1770065303401,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bulcan.2018.07.015","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:00:09Z","timestamp":1537419609000},"page":"925-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Precision medicine and bladder cancer heterogeneity"],"prefix":"10.1016","volume":"105","author":[{"given":"Guofeng","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuecheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2018.07.015_bib0155","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"Ca A Cancer J Clin"},{"issue":"4","key":"10.1016\/j.bulcan.2018.07.015_bib0160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2014.04.014","article-title":"Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications","volume":"67","author":"Gerlinger","year":"2014","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.07.015_bib0165","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.molonc.2016.08.003","article-title":"Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma","volume":"10","author":"Thomsen","year":"2016","journal-title":"Mol Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2018.07.015_bib0170","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1158\/0008-5472.CAN-16-0436","article-title":"Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma","volume":"76","author":"Lamy","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.bulcan.2018.07.015_bib0175","first-page":"355","article-title":"Tumor progression","volume":"17","author":"Foulds","year":"1957","journal-title":"Cancer Res"},{"issue":"4260","key":"10.1016\/j.bulcan.2018.07.015_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bulcan.2018.07.015_bib0185","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.cell.2015.07.039","article-title":"The Life History of 21 Breast Cancers (vol 149, pg 994, 2012)","volume":"162","author":"Nik-Zainal","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bulcan.2018.07.015_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000370165","article-title":"Bladder tumor heterogeneity: the impact on clinical treatment","volume":"95","author":"Chen","year":"2015","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.bulcan.2018.07.015_bib0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/path.2945","article-title":"The human urothelium consists of multiple clonal units, each maintained by a stem cell","volume":"225","author":"Gaisa","year":"2011","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.07.015_bib0200","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.bbadis.2014.07.007","article-title":"Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer","volume":"1842","author":"Ojha","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.bulcan.2018.07.015_bib0205","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2018.07.015_bib0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2047-217X-1-12","article-title":"Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer","volume":"1","author":"Li","year":"2012","journal-title":"GigaScience"},{"key":"10.1016\/j.bulcan.2018.07.015_bib0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fonc.2012.00051","article-title":"Differing Von Hippel Lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma","volume":"2","author":"Vaziri","year":"2012","journal-title":"Front Oncol"},{"issue":"7403","key":"10.1016\/j.bulcan.2018.07.015_bib0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bulcan.2018.07.015_bib0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","article-title":"Urothelial tumorigenesis: a tale of divergent pathways","volume":"5","author":"Wu","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2018.07.015_bib0230","doi-asserted-by":"crossref","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","article-title":"Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer","volume":"7","author":"Thomsen","year":"2017","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.bulcan.2018.07.015_bib0235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"7330","key":"10.1016\/j.bulcan.2018.07.015_bib0240","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"issue":"7467","key":"10.1016\/j.bulcan.2018.07.015_bib0245","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bulcan.2018.07.015_bib0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1471-4906(01)01863-4","article-title":"Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation","volume":"22","author":"Buckley","year":"2001","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.07.015_bib0255","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jcp.24347","article-title":"Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells","volume":"228","author":"Polanska","year":"2013","journal-title":"J Cell Physiol"},{"issue":"19","key":"10.1016\/j.bulcan.2018.07.015_bib0260","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.bulcan.2018.07.015_bib0265","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1101\/gad.13.11.1382","article-title":"Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis","volume":"13","author":"Coussens","year":"1999","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.bulcan.2018.07.015_bib0270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1\u00b1- and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bulcan.2018.07.015_bib0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.07.015_bib0280","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2018.07.015_bib0285","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: a moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2018.07.015_bib0290","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/modpathol.2017.188","article-title":"Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression","volume":"31","author":"Tretiakova","year":"2017","journal-title":"Mod Pathol"},{"issue":"26","key":"10.1016\/j.bulcan.2018.07.015_bib0295","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7492","key":"10.1016\/j.bulcan.2018.07.015_bib0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Network","year":"2014","journal-title":"Nature"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:29:46Z","timestamp":1757791786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118302376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0007455118302376"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine and bladder cancer heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}